Navigation Links
Scientists to study the role genes play in treating TB
Date:10/25/2012

The University of Liverpool has been awarded funding to determine whether differences in our genes determine how patients respond to drugs used to treat Tuberculosis (TB) in Sub-Saharan Africa.

Professor Andrew Owen, from the University's Department of Molecular and Clinical Pharmacology, is part of an international research team that will explore why some patients respond positively to anti-TB drug treatment while in other patients the treatments fail or the patients experience toxicity. In patients with HIV/AIDS the percentage of patients that are not cured by therapy is even higher.

TB is the second leading cause of death from an infectious disease worldwide after HIV/AIDS. In 2010 there were 8.8 million new cases of TB and 1.1 million deaths, including 350,000 deaths from TB among people with HIV. In Sub-Saharan Africa TB poses a major public health problem and is the leading killer of people living with HIV, causing one quarter of all deaths.

Professor Owen said: "There is a much greater understanding of genes which affect how we react and respond to drugs used in other diseases such as HIV than there is for TB. This project will study the genes of patients being treated with the four main anti-TB drugs, and also with a new drug which is in development, using clinical trial sites in Benin, Senegal and South Africa. The study aims to explore and determine genetic differences which affect the effectiveness and reaction to anti-TB drugs. It is funded through the H3Africa project which is led by African scientists and one of its aims is to foster capacity-building for research in Sub Saharan Africa."

The standard treatment for TB is a six-month course of four drugs taken daily for two months, followed by two drugs taken for a four-month period but as many as 10 per cent of patients do not respond to this treatment. Patients who have been treated with anti-TB drugs have an increased risk of spreading a strain of TB th
'/>"/>

Contact: Sarah Stamper
sarah.stamper@liv.ac.uk
01-517-943-044
University of Liverpool
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Kessler Foundation scientists awarded New Jersey grants for brain injury research
2. Scientists Focus on Factors Behind Asthma Attacks
3. Einstein-Montefiore scientists awarded 2 NCI Provocative Questions grants
4. Leading stem cell scientists to focus on diabetes, eye diseases at Cedars-Sinai symposium
5. Diets High in Fructose May Harm Liver in Some, Scientists Warn
6. Cardiff scientists bid to develop anthrax vaccine to counteract world bioterrorism threat
7. Scripps Research Institute scientists show protein linked to hunger also implicated in alcoholism
8. Scientists Spot 5 Genes That Help Shape Faces
9. Eight scientists honored in first annual Golden Goose Awards
10. Scientists Map Genetic Blueprint of Heart
11. Scientists use sound waves to levitate liquids, improve pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... Wallingford, CT (PRWEB) June 03, 2015 ... devices, announces today since June has been designated as ... Company commends the Tucson, AZ. Police Department for its ... that its personnel utilized their Individual First Aid Kits ... help civilians involved in shootings, stabbings or traffic accidents. ...
(Date:6/3/2015)... Researchers at the University of Western Australia compared ... tried-and-true marker mesothelin is the best option available. Surviving ... Click here to read it now. , ... Diseases say, even though a mesothelin test can sometimes ... fibulin-3 for identifying mesothelioma. , “Preliminary results on ...
(Date:6/3/2015)... According to an article published on ... fake oxycodone pills which actually contained the potent addictive ... legitimate, and even sported the “A/215” imprint common on ... 30 mg oxycodone to be exceptionally critical of their ... them illegally on the street. Fentanyl is an opiate-based ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 Fourroux Prosthetics, ... Duluth, GA will celebrate its grand opening with a ... The first prosthetic center of its kind in the ... family unmatched care and outcomes through use of patented ... CPO & CEO of Fourroux Prosthetics, states, “Our goal ...
(Date:6/3/2015)... MN (PRWEB) June 03, 2015 DailyEndorphin ... wellness "events" programming module. With this highly configurable ... run and report on many components of its wellness ... at no additional charge. , With this new module, ... Integrate DE challenges, (2) Create participant surveys, (3) Continually ...
Breaking Medicine News(10 mins):Health News:Z-Medica Commends Tucson Police Department for Trauma Kit Utilization 2Health News:Analysis Reveals Gold Standard Mesothelioma Biomarker Still the Best, According to Surviving Mesothelioma 2Health News:Fake Oxycodone Pills of Fentanyl Discovered in Tennessee by Police 2Health News:Fake Oxycodone Pills of Fentanyl Discovered in Tennessee by Police 3Health News:Fourroux Prosthetics Atlanta to Have Grand Opening Gala & Ribbon Cutting Ceremony 2Health News:DailyEndorphin Launches Wellness "Events" Portal 2
... Way to Fight Rare, but Deadly, Side Effect ... St. Luke,s Medical Center have developed a technique ... from natalizumab (Tysabri(R)), a drug that fights multiple ... called progressive multifocal leukoencephalopathy (PML)."This virus looks like ...
... J. Betters, president and chief executive officer of C. ... submitted an offer to purchase the former Aliquippa Hospital. ... awaiting a response from the hospital property owners and ... future uses for the hospital property., ...
... a woman blind in one eye. As she copes with ... uninjured eye begins to blur, and the eye becomes red ... ophthalmia, occurs when vision is lost in one eye through ... attacks the remaining healthy eye. Left untreated, a person can ...
... These patients were twice as likely to get clot-busting drug, ... who get to a hospital no more than an hour ... as likely to get the powerful clot-dissolving drug that is ... Of the more than 100,000 people treated for stroke at ...
... United BioSource Corporation (UBC) and CogState ... renew the strategic relationship the two companies ... CogState,s ClinicalTrials software for computerized cognitive testing ... and UBC remain committed to supporting cognitive ...
... Feb. 18 Spurred by seizures of vital doctor-prescribed ... Zealand to U.S. citizens, the publishers of three Seniors, ... Food and Drug Administration to halt the arbitrary seizures ... medicines to U.S. seniors and others.The publishers are Frank ...
Cached Medicine News:Health News:Research Brings New Hope to Multiple Sclerosis Patients 2Health News:New surgical implant tested at U-Iowa prevents total blindness 2Health News:Fast Arrival at Hospital After Stroke Pays Off 2Health News:Fast Arrival at Hospital After Stroke Pays Off 3Health News:Seniors' Website Publishers Ask President to Curtail FDA Seizures of Vital Medicines 2
(Date:6/3/2015)... DUBLIN , June 02, 2015 ... the addition of the "2015 Strategies in ... to their offering. Highlights of the ... of the US tumor marker testing market. ... practice, as well as key economic, regulatory, demographic, ...
(Date:6/3/2015)... -- AVT, Inc. (OTC Markets: AVTC) ( www.autoretail.com ), ... that their customer, Pharmabox, has introduced the world,s 1 ... over 140 top selling brand name items typically found ... Aid-type store. As published in the ... -based Pharmabox worked with AVT to develop a ...
(Date:6/3/2015)... June 3, 2015  Halozyme Therapeutics, Inc. (NASDAQ: ... and license agreement with AbbVie (NYSE: ABBV ... compounds with Halozyme,s ENHANZE ™ platform. ... Halozyme will receive an initial $23 million payment, ... for each of up to nine collaboration targets. ...
Breaking Medicine Technology:United States Strategies in the Tumor Marker Testing Market 2015 2Pharmabox Introduces New Concept with a Boldly Designed Automated Retailing System 2Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie 2Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie 3
... Patient Safety Technologies, Inc. (OTC Bulletin Board: PSTX) (the "Company") announced ... financing.  The new capital will primarily be used to fund working ... , , ... has been appointed as President, Chief Executive Officer and Board ...
... PRINCETON, N.J. , June 25 Soligenix, ... a late-stage biopharmaceutical company, announced today the publication of ... of Vaccine , which describes protection from mucosal ... of RiVax™, the Company,s vaccine against ricin toxin. The ...
Cached Medicine Technology:Patient Safety Technologies Completes $6.0 Million Equity Financing 2Patient Safety Technologies Completes $6.0 Million Equity Financing 3Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration 2Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration 3Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration 4Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration 5Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration 6Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration 7
VIKIA Rota-Adeno is a rapid, qualitative, chromatographic immunoassay which simultaneously detects rotaviruses and adenoviruses in stool specimens. Rotaviruses and adenoviruses are responsible for,th...
A direct enzyme immunoassay for detection of gr. A rotavirus in fecal specimens....
The ELISA test is used for detection and semi quantitation of igG antibodies to proteinase 3(PR3) in human sera, as an aid to the diagnosis is of Wegener's granulomatosis....
ELISA for Anti-Proteinase 3 PR3 (cANCA)....
Medicine Products: